Abstract
Full spectrum flow cytometry is a powerful tool for immune monitoring on a single-cell level and with currently available machines, panels of 40 or more markers per sample are possible. However, with an increased panel size, spectral unmixing issues arise, and appropriate single stain reference controls are required for accurate experimental results and to avoid unmixing errors. In contrast to conventional flow cytometry, full spectrum flow cytometry takes into account even minor differences in spectral signatures and requires the full spectrum of each fluorochrome to be identical in the reference control and the fully stained sample to ensure accurate and reliable results. In general, using the cells of interest is considered optimal, but certain markers may not be expressed at sufficient levels to generate a reliable positive control. In this case, compensation beads show some significant advantages as they bind a consistent amount of antibody independent of its specificity. In this study, we evaluated two types of manufactured compensation beads for use as reference controls for full spectrum cytometry and compared them to human and murine primary leukocytes. While most fluorochromes show the same spectral profile on beads and cells, we demonstrate that specific fluorochromes show a significantly different spectral profile depending on which type of compensation beads is used, and some fluorochromes should be used on cells exclusively. Finally, we provide a list of appropriate reference controls for 30 of the most commonly used and commercially available fluorochromes.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Conflict of interest disclosure: The authors declare no financial conflicts of interest.
Funding: This work was supported by the German Research Foundation (DFG; CRC1382, SFB/TRR 296 and SPP2306), the Else-Kröner-Fresenius-Stiftung (Grant-ID 2021_EKEA.145) and Charité 3R| Replace - Reduce – Refine.
Ethics statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local ethics committee at Charité Universitätsmedizin Berlin, Germany (ethical approval number EA2/065/21). Informed consent was obtained from all subjects involved in the study and is kept on file.